Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Depreciation and Depletion (2017 - 2025)

Cue Biopharma (CUE) has disclosed Depreciation and Depletion for 9 consecutive years, with $65000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion fell 31.58% to $65000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $335000.0 through Dec 2025, down 13.66% year-over-year, with the annual reading at $336000.0 for FY2025, 12.73% down from the prior year.
  • Depreciation and Depletion hit $65000.0 in Q4 2025 for Cue Biopharma, down from $76000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $232000.0 in Q3 2021 to a low of $65000.0 in Q4 2025.
  • Historically, Depreciation and Depletion has averaged $149055.7 across 5 years, with a median of $122500.0 in 2023.
  • Biggest five-year swings in Depreciation and Depletion: grew 23.08% in 2021 and later plummeted 52.83% in 2023.
  • Year by year, Depreciation and Depletion stood at $227114.0 in 2021, then dropped by 11.5% to $201000.0 in 2022, then decreased by 27.86% to $145000.0 in 2023, then tumbled by 34.48% to $95000.0 in 2024, then plummeted by 31.58% to $65000.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for CUE at $65000.0 in Q4 2025, $76000.0 in Q3 2025, and $97000.0 in Q2 2025.